Chemed Corp SEC Filings

Chemed Corp. insider Kevin J. McNamara, who serves as director, president and CEO, reported a sale of company stock. On 11/24/2025, he sold 2,000 shares of Chemed capital stock in an open market transaction coded as "S" for sale. The weighted average sale price was $437.55 per share, with individual trade prices ranging from $436.13 to $438.53.

After this transaction, McNamara beneficially owns 94,197 shares of Chemed stock in direct form. He has indicated a willingness to provide detailed breakdowns of the number of shares sold at each separate price within the reported range to Chemed, its security holders, or SEC staff upon request.

CHE has a Form 144 notice indicating a planned sale of 2,000 common shares. The shares are to be sold through Raymond James & Associates on or about 11/24/2025 on the NYSE, with an aggregate market value of $876,000. Shares outstanding were 14,110,000; this is a baseline figure, not the amount being sold.

The seller acquired the shares through stock awards from the issuer in 2016. The filing also lists prior sales over the past three months by Kevin J McNamara, including 1,000 common shares for gross proceeds of $460,647 and 2,000 common shares for $922,794, both on 09/26/2025. The signer represents they are not aware of undisclosed material adverse information about the issuer.

Chemed Corp executive vice president reports small share transfer

Chemed Corp executive vice president Spencer S. Lee reported a change in ownership of company stock. On 11/19/2025, Lee disposed of 60 shares of Chemed Corp capital stock in a transaction coded "G," which typically denotes a gift or similar transfer, at a reported price of $0.00 per share. After this transaction, Lee beneficially owns 14,567 shares directly.

Chemed (CHE) reported Q3 2025 results. Service revenues and sales were $624.9 million, up from $606.2 million a year ago. Net income was $64.2 million versus $75.8 million, and diluted EPS was $4.46 compared with $5.00. Segment revenue was $407.7 million at VITAS and $217.2 million at Roto‑Rooter.

For the first nine months, revenue reached $1.89 billion (vs. $1.79 billion) with net income of $188.5 million (vs. $211.7 million). Cash from operations was $254.7 million, supporting $253.5 million of share repurchases year‑to‑date, including $180.8 million in Q3. Cash was $129.8 million, and approximately $404.5 million remained available under the revolving credit facility. The company paid a $0.60 per share dividend in Q3; shares outstanding were 14,164,195 as of September 30, 2025. In VITAS, an Administrative Law Judge largely upheld higher‑level‑of‑care billings; the Medicare Administrative Contractor refunded the previously deposited amount, reducing the overpayment to a de minimis figure. Board repurchase authorization remaining was $301.8 million.

Chemed Corp (CHE) reported an insider equity award on Form 4. Joel L. Wherley, CEO of VITAS Healthcare, received a stock option grant covering 17,476 shares at an exercise price of $443.79 on 10/21/2025.

The options vest in three equal annual installments commencing 10/21/2026 and expire on 10/21/2030. Following the transaction, Wherley beneficially owned 32,819 derivative securities directly. No non-derivative share transactions were reported in Table I.

Chemed Corp (CHE) executive vice president Spencer S. Lee reported a stock option grant. On 10/21/2025, he received 12,759 stock options with an exercise price of $443.79 per share, expiring on 10/21/2030. The options vest in three equal annual installments beginning 10/21/2026. Following this grant, he beneficially owned 28,196 derivative securities, held directly.

Chemed Corp (CHE) reported an insider equity award. On 10/21/2025, the company granted its VP and Chief Legal Officer a stock option for 15,017 shares at an exercise price of $443.79 per share, expiring on 10/21/2030. The option vests in three equal annual installments commencing 10/21/2026. After this grant, the reporting person beneficially owned 38,067 derivative securities, held directly.

Chemed Corp (CHE) reported a Form 4 for VP & Chief Financial Officer Michael D. Witzeman, showing a grant of 19,486 stock options on 10/21/2025. Each option has an exercise price of $443.79 and is a right to buy capital stock, expiring on 10/21/2030.

The award vests in three equal annual installments commencing 10/21/2026. Following this transaction, the reporting person beneficially owned 53,970 derivative securities, held in Direct ownership form.